1. Home
  2. ADV vs CDNA Comparison

ADV vs CDNA Comparison

Compare ADV & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADV
  • CDNA
  • Stock Information
  • Founded
  • ADV 1987
  • CDNA 1998
  • Country
  • ADV United States
  • CDNA United States
  • Employees
  • ADV N/A
  • CDNA N/A
  • Industry
  • ADV Business Services
  • CDNA Medical Specialities
  • Sector
  • ADV Consumer Discretionary
  • CDNA Health Care
  • Exchange
  • ADV Nasdaq
  • CDNA Nasdaq
  • Market Cap
  • ADV 415.1M
  • CDNA 1.0B
  • IPO Year
  • ADV N/A
  • CDNA 2014
  • Fundamental
  • Price
  • ADV $1.41
  • CDNA $18.85
  • Analyst Decision
  • ADV Strong Buy
  • CDNA Buy
  • Analyst Count
  • ADV 1
  • CDNA 6
  • Target Price
  • ADV $2.50
  • CDNA $30.33
  • AVG Volume (30 Days)
  • ADV 823.4K
  • CDNA 959.0K
  • Earning Date
  • ADV 08-06-2025
  • CDNA 07-30-2025
  • Dividend Yield
  • ADV N/A
  • CDNA N/A
  • EPS Growth
  • ADV N/A
  • CDNA N/A
  • EPS
  • ADV N/A
  • CDNA 1.07
  • Revenue
  • ADV $3,526,704,000.00
  • CDNA $346,421,000.00
  • Revenue This Year
  • ADV N/A
  • CDNA $13.31
  • Revenue Next Year
  • ADV N/A
  • CDNA $15.46
  • P/E Ratio
  • ADV N/A
  • CDNA $17.58
  • Revenue Growth
  • ADV N/A
  • CDNA 25.92
  • 52 Week Low
  • ADV $1.04
  • CDNA $14.09
  • 52 Week High
  • ADV $4.16
  • CDNA $34.84
  • Technical
  • Relative Strength Index (RSI)
  • ADV 44.69
  • CDNA 51.86
  • Support Level
  • ADV $1.28
  • CDNA $18.64
  • Resistance Level
  • ADV $1.70
  • CDNA $19.84
  • Average True Range (ATR)
  • ADV 0.13
  • CDNA 0.80
  • MACD
  • ADV -0.03
  • CDNA -0.07
  • Stochastic Oscillator
  • ADV 4.35
  • CDNA 25.60

About ADV Advantage Solutions Inc.

Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: